Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
NCT ID: NCT07008144
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
5954 participants
INTERVENTIONAL
2025-12-31
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg/day (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Digital App and Platform for Supporting Medicines Control and Optimization in Older Individuals With Heart Failure
NCT05353803
Efficacy of a Disease Management Program in Very Old Patients With Heart Failure
NCT01076465
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
NCT05972746
NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction
NCT02807168
Nt-proBNP Versus Clinical Guided Discharge in Acute Heart Failure
NCT01299350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Objective The main goal is to assess whether these alerts reduce the number of elderly hospitalized patients receiving inappropriate digoxin dosages.
Study Design and Duration The study will last 18 months in total, with a 12-month data collection period at each site (6 months before and 6 months after the intervention).
Sample Size and Population To detect a 25% reduction in inappropriate digoxin prescriptions with 80% power and a 0.05 alpha risk, the study requires 2,977 patients in both the pre- and post-intervention groups. Inclusion criteria include hospitalized men and women aged 65 and older. No patient exclusions are anticipated.
Statistical Analysis The primary analysis will compare the proportion of patients receiving digoxin doses above the recommended level before and after the intervention using the Chi-square test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Before intervention
In this group, the outcome will be measured before the intervention is implemented at the center
No interventions assigned to this group
Post intervention
In this group, the outcome will be measured after the intervention is implemented at the center
Digoxin alarm
A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digoxin alarm
A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized in inpatient wards of the study centers during the study period.
Exclusion Criteria
* Patients without complete data available
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Consorci Sanitari de l'Alt Penedès i Garraf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alejandro Rodríguez Molinero
Role: STUDY_DIRECTOR
Consorci Sanitari de l'Alt Penedès i Garraf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Consorci Sanitari Alt Penedès-Garraf-Hospital de Vilafranca
Vilafranca del Penedès, Barcelona, Spain
Consorci Sanitari Alt Penedès-Garraf Hospital Sant Camil
Barcelona, Spain, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSAPG-73
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.